(2E)-5-amino-N,5-dimethyl-N-[(1R)-1-{methyl[(1R)-1-(methylcarbamoyl)-2-phenylethyl]carbamoyl}-2-(naphthalen-2-yl)ethyl]hex-2-enamide

• ChemBase编号: 178039
• 分子式: C32H40N4O3
• 平均质量: 528.685
• 单一同位素质量: 528.31004116
• SMILES: c1ccc2c(c1)cc(cc2)C[C@H](C(=O)N([C@@H](C(=O)NC)Cc1ccccc1)C)N(C(=O)/C=C/CC(N)(C)C)C
• Canonical SMILES: CNC(=O)[C@H](N(C(=O)[C@H](N(C(=O)/C=C/CC(N)(C)C)C)Cc1ccc2c(c1)cccc2)C)Cc1ccccc1
• InChI: InChI=1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1
• InChIKey: WURGZWOTGMLDJP-ZCYANPAGSA-N

名称和登记号

名称

• IUPAC标准名: (2E)-5-amino-N,5-dimethyl-N-[(1R)-1-{methyl[(1R)-1-(methylcarbamoyl)-2-phenylethyl]carbamoyl}-2-(naphthalen-2-yl)ethyl]hex-2-enamide
• IUPAC传统名: (2E)-5-amino-N,5-dimethyl-N-[(1R)-1-{methyl[(1R)-1-(methylcarbamoyl)-2-phenylethyl]carbamoyl}-2-(naphthalen-2-yl)ethyl]hex-2-enamide
• 别名: N-[(2E)-5-Amino-5-methyl-1-oxo-2-hexen-1-yl]-N-methyl-3-(2-naphthalenyl)-D-alanyl-N,Nα-Dimethyl-D-phenylalaninamide; NN 703; NNC 26-0703; Tabimorelin

登记号

• CAS号: 193079-69-5
• PubChem SID: 164233949
• PubChem CID: 9810101

理论计算性质

• Acid pKa: 15.645596
• 质子受体: 4
• 质子供体: 2
• LogD (pH = 5.5): 0.584644
• LogD (pH = 7.4): 0.93289703
• Log P: 3.6109192
• 摩尔折射率: 157.0044 cm^3
• 极化性: 61.836735 Å^3
• 极化表面积: 95.74 Å^2
• 可自由旋转的化学键: 11
• 里宾斯基五规则: false

详细说明

Toronto Research Chemicals - T003500

NN703 (Tabimorelin) is an orally active growth hormone (GH) secretagogue intended for use as an alternative to daily injections of GH. In vitro studies in human liver microsomes have indicated that NN703 is a mechanism-based inhibitor of CYP3A4.

参考文献

• Fabre, G., et al.: Biochem. Pharmacol., 37, 4389 (1988)
• Thummel, K., et al.: Clin. Pharmacol. Ther., 59, 491 (1988)
• Yu, D., et al.: J. Clin. Pharmacol., 39, 1203 (1988)